Rheinmetall Wins Moroccan Field Hospital Contract But Faces €300 Million Frigate Revenue Hole
Published on 07/05/2026 at 12:54 | Redaktion boerse-global.de
A €300 million hole in the order book and a fresh export deal in North Africa are pulling Rheinmetall in opposite directions this week. The Düsseldorf-based defence contractor signed in June 2026 to supply the Kingdom of Morocco with seven mobile field hospitals, yet the cancellation of the F126 frigate programme by the German defence ministry continues to cast a shadow over the company's financial outlook.
The shares closed Friday at €1,097.00, down 0.51% on the day, but that still left them with a weekly gain of 16.63%. The stock has rallied sharply from its 52-week low of €902.50, set on 25 June 2026, though it remains 45.01% below the September 2025 high of €1,995.00. On a year-to-date basis, the equity is still nursing a 31.50% decline.
Morocco contract leverages Ukraine battlefield experience
The order, placed via subsidiary Rheinmetall Mobile Systeme GmbH, carries a mid-double-digit million euro value. One hospital will go to the Moroccan defence ministry, while the remaining six will be operated by the interior ministry. The technology behind the mobile medical units was previously validated in service with Ukrainian armed forces — a selling point that evidently resonated in Rabat.
This transaction underscores Rheinmetall’s strategy of pushing beyond its traditional heavy weapons portfolio. Mobile medical infrastructure is now emerging as a stand-alone export category, helping to diversify revenue streams away from the domestic political turbulence that has engulfed the F126 programme.
Should investors sell immediately? Or is it worth buying Rheinmetall?
Frigate cancellation weighs on second-quarter numbers
The F126 setback hit in late June when the federal defence ministry awarded the frigate project to rival TKMS instead. Rheinmetall has since warned that the cancellation could slice up to €300 million off full-year revenue in 2026, barring countermeasures. The group also expects second-quarter order intake to settle at a low double-digit billion level, well short of the roughly €20 billion the management had earlier signalled. The cancelled frigate programme represented less than 3% of the long-term forecast, the company noted.
Analysts split on the damage
Wall Street responded with divergent views. JPMorgan’s David H. Perry cut his price target from €1,500 to €1,350, maintaining a “Neutral” rating. He cited sluggish order activity from the German government and a faster-than-expected shift in defence technology as reasons for caution, adding that the group’s targets for the end of the decade now look “extremely ambitious”.
Barclays took a more optimistic stance. The British bank trimmed its target only modestly, from €2,035 to €2,000, and kept a “Buy” recommendation. Barclays analysts anticipate second-quarter revenue growth of 59%, pointing to strong underlying operating momentum that they believe will offset the frigate loss.
Rheinmetall at a turning point? This analysis reveals what investors need to know now.
August 6 earnings to provide clarity
Investors remain on edge ahead of the second-quarter release scheduled for 6 August 2026, when Rheinmetall will deliver a detailed assessment of the F126 fallout and its implications for the full-year guidance. The short-term volatility is severe: the 30-day annualised volatility stands at 69.10%, while the RSI indicator at 46.5 sits in neutral territory.
The Moroccan hospital order does little to mend the immediate revenue gap, but it demonstrates that Rheinmetall’s international business continues to expand independently of Germany’s domestic defence debates. The August update will show whether that momentum can offset the damage from a lost flagship programme.
Ad
Rheinmetall Stock: New Analysis - 5 July
Fresh Rheinmetall information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
